152
Participants
Start Date
December 20, 2024
Primary Completion Date
November 1, 2026
Study Completion Date
April 30, 2028
Enzalutamide
The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Apalutamide (Erleada™) 60 mg or 240 mg tablets
The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Darolutamide (Nubeqa®) 300 mg tablets
The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Taxotere (docetaxel)
The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Abiraterone acetate + Prednisone or Prednisolone
The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
RECRUITING
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ONCOLOGIA MEDICA, Rome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER